Physician profile
Laura E Albright
NPI 1912388018
$3,777.80
in general payments reported to CMS, 2019-2025
28 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.94 · 2020: $50.67 · 2021: $156 · 2022: $237 · 2023: $289 · 2024: $1,511 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $952.53 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $710.55 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $414.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $318.27 | 2019-2025 | Evenity, Prolia, Otezla |
| Pfizer INC. | $227.84 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $203.36 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.46 | 2023-2025 | Jardiance |
| Exact Sciences Corporation | $100.63 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Lundbeck LLC | $80.80 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $78.87 | 2024-2025 | Auvelity |
| Glaxosmithkline, LLC. | $75.60 | 2024-2025 | Trelegy Ellipta, Bexsero |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $74.27 | 2024-2025 | Caplyta |
| Abbott Laboratories | $59.68 | 2024-2025 | Freestyle Libre 3 |
| Viiv Healthcare Company | $52.57 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $49.28 | 2024-2025 | Rexulti |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $32.63 | 2023-2025 | Dexcom G6 Transmitter |
| Almatica Pharma LLC | $27.81 | 2024 | Loreev Xr |
| Rgh Enterprises LLC | $27.54 | 2025 | |
| Genentech USA, INC. | $24.62 | 2024 | Xolair |
| Biohaven Pharmaceuticals, INC. | $22.57 | 2021 | |
| Astellas Pharma US INC | $19.63 | 2024 | Veozah |
| Merck Sharp & Dohme LLC | $19.01 | 2024 | Gardasil 9, Gardasil, Capvaxive |
| Supernus Pharmaceuticals, INC. | $18.06 | 2025 | Qelbree |
| Insulet Corporation | $17.52 | 2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $17.33 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.80 | 2025 | Trintellix |
| Boston Scientific Corporation | $13.66 | 2025 | Watchman Flx |
| Esperion Therapeutics, INC. | $11.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Albright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.